C12N 2770/36145
Special targeting system for viral vectors
C12N2770/36145 (Special targeting system for viral vectors) appears on 13 US grants and 31 published applications in this corpus.
Search patents in C12N- Granted patents
- 13
- Published applications
- 31
- Assignees
- 17
- Inventors
- 34
- Latest grant
- 30 Jul 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 1 | 1 |
| 2003 | 0 | 3 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 2 | 3 |
| 2010 | 0 | 2 |
| 2011 | 0 | 2 |
| 2012 | 3 | 1 |
| 2013 | 0 | 1 |
| 2014 | 1 | 0 |
| 2015 | 0 | 2 |
| 2016 | 2 | 6 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 1 | 1 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 2 | 1 |
| 2024 | 1 | 2 |
| 2025 | 0 | 1 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon30 Jul 2024US 12,049,639 B2The USA, as represented by the Secretary, Dept. of Health and Human Services
- Compositions and methods for the prevention and treatment of rabies virus infection22 Aug 2023US 11,730,804 B1Replicate Bioscience, Inc.
- Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon8 Aug 2023US 11,718,861 B2The USA, as represented by the Secretary, Dept. of Health and Human Services
- Delivery of packaged RNA to mammalian cells21 Jan 2020US 10,538,743 B2The USA, as represented by the Secretary, Dept. of Health and Human Services
- Delivery of packaged RNA to mammalian cells29 Nov 2016US 9,506,041 B2The United States of America, as represented by the Secretary, Dept. of Health and Human Services
- Sarna delivery system, preparation method therefor and use thereof23 Apr 2026US 2026/0110000 A1Zhejiang Free Trade Zone Hongan Base Biotechnology Co., Ltd.
- Compositions and methods for the prevention and treatment of rabies virus infection12 Jun 2025US 2025/0186574 A1Replicate Bioscience, Inc.
- Compositions of glycoprotein particles27 Jun 2024US 2024/0207196 A1Scribe Therapeutics Inc.
- Modified alphavirus vectors23 May 2024US 2024/0167057 A1Gritstone Bio, Inc.
- Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon17 Aug 2023US 2023/0257775 A1The USA as represented by the Secretary of Health and Human Services
Most cited
By later US patents
- Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A22US 6,432,699 B1New York University · 2002
- Compositions and methods for generating an immune response utilizing alphavirus-based vector systems20US 8,647,864 B2Novartis AG · 2014
- Chimeric alphavirus replicon particles20US 9,255,126 B2Novartis Vaccines and Diagnostics, Inc. · 2016
- Chimeric alphavirus replicon particles19US 7,572,453 B2Novartis Vaccines and Diagnostics, Inc. · 2009
- Chimeric alphavirus replicon particles17US 7,531,180 B2Novartis Vaccines and Diagnostics, Inc. · 2009